{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:28:06Z","timestamp":1774686486911,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,10,12]],"date-time":"2005-10-12T00:00:00Z","timestamp":1129075200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The study aims to assess the pattern of thyroid response to combination Interferon-\u03b12\u03b2 (IFN-\u03b1) and Ribavirin (RBV) anti-viral therapy in an Australian hepatitis C cohort. These include the prevalence of thyroid dysfunction (TD) including hyperthyroidism and hypothyroidism and their possible predictors, the common overall pattern of thyroid function tests whilst receiving therapy and TD outcomes, and the correlation with HCV status outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective analysis of all medical records was performed to assess thyroid function in Hepatitis C Virus (HCV) patients who were treated at the Hunter Area hepatitis C treatment center between 1995 and March 2004. The centre is part of the John Hunter hospital, a major tertiary referral centre in New South Wales, Australia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were 272 cases available for review. The prevalence of TD is 6.7 percent and is made up predominantly of females (80 percent). There were 3 (1.1 percent) cases of hyperthyroidism with 2 (67 percent) females. Thirteen out of fifteen (80 percent) cases of hypothyroidism were females with the overall prevalence of 5.5 percent. The majority of hypothyroid patients still required Thyroxine supplement at the end of follow up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Ninety three percent of HCV treated patients have intact thyroid function at the end of treatment. The predominant TD is hypothyroidism. The predominant pattern of thyrotoxicosis (TTX) is that of thyroiditis although the number is small. Graves' like disease was not observed. People with pre-existing thyroid auto-antibodies should be closely monitored for thyroid dysfunction, particularly hypothyroidism.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6823-5-8","type":"journal-article","created":{"date-parts":[[2005,10,12]],"date-time":"2005-10-12T06:13:58Z","timestamp":1129097638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-\u03b12\u03b2 and Ribavirin"],"prefix":"10.1186","volume":"5","author":[{"given":"Huy A","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey L","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G","family":"Batey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,10,12]]},"reference":[{"key":"21_CR1","volume-title":"Annual report of the National Notifiable Diseases Surveillance System","author":"Australia's notifiable diseases status","year":"2002","unstructured":"Australia's notifiable diseases status: Annual report of the National Notifiable Diseases Surveillance System. 2002, accessed 29-September-2005., [http:\/\/www.cda.gov.au]"},{"issue":"RR-19","key":"21_CR2","first-page":"1","volume":"47","author":"CDC","year":"1998","unstructured":"CDC: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related disease. MMWR Recomm Rep. 1998, 47 (RR-19): 1-40.","journal-title":"MMWR Recomm Rep"},{"key":"21_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199908193410802","volume":"341","author":"MJ Alter","year":"1999","unstructured":"Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999, 341: 556-562. 10.1056\/NEJM199908193410802.","journal-title":"N Engl J Med"},{"key":"21_CR4","first-page":"140","volume-title":"An overview of antiviral therapy for chronic hepatitis C infection","author":"W Sievert","year":"2001","unstructured":"Sievert W: An overview of antiviral therapy for chronic hepatitis C infection. Edited by: Crofts N, Dore G, Locarnini S. 2001, Hepatitis C: an Australian perspective. Melbourne: IP Communications, 140-154."},{"key":"21_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/0168-8278(95)80291-6","volume":"22","author":"P Marcellin","year":"1995","unstructured":"Marcellin P, Pouteau M, Benhamou J-P: Hepatitis C viral infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995, 22: 364-369. 10.1016\/0168-8278(95)80291-6.","journal-title":"J Hepatol"},{"key":"21_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","volume":"25","author":"T Okanoue","year":"1996","unstructured":"Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K: Side effects of high dose interferon therapy for chronic hepatitis C. J Hepatol. 1996, 25: 283-291. 10.1016\/S0168-8278(96)80113-9.","journal-title":"J Hepatol"},{"key":"21_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1046\/j.1365-2265.1996.751768.x","volume":"44","author":"M Marazuela","year":"1996","unstructured":"Marazuela M, Garcia-Buey L, Gonzalez-Fernandez F, Garcia-Monzon D, Arranz A, Borque MJ, Moreno-Otero R: Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-\u03b1 therapy. Clin Endocrinol. 1996, 44: 635-642. 10.1046\/j.1365-2265.1996.751768.x.","journal-title":"Clin Endocrinol"},{"key":"21_CR8","first-page":"331","volume-title":"Chapter 10, Thyroid Physiology and Diagnostic Evaluation of Patients with Thyroid Disorders. Williams Textbook of Endocrinology","author":"PR Larsen","year":"2003","unstructured":"Larsen PR, Davies TF, Schlumberger M-J, Hay ID: Chapter 10, Thyroid Physiology and Diagnostic Evaluation of Patients with Thyroid Disorders. Williams Textbook of Endocrinology. Edited by: Larsen PR, Kronenberg HM, Melmed S and Polonsky KS. 2003, Saunders, Elsevier Science Ltd, 331-373. 10","edition":"10"},{"key":"21_CR9","first-page":"2030","volume-title":"Immune modulation: interferons and interleukins","author":"M Pegram","year":"1996","unstructured":"Pegram M, Mitsuyasu RT: Immune modulation: interferons and interleukins. Edited by: Rich RR, Fleisher TA. 1996, Clinical Immunology: Principles and Practice St. Louis: CV Mosby, 2030-2036."},{"key":"21_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archinte.158.13.1445","volume":"158","author":"L Fernandez-Soto","year":"1998","unstructured":"Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J: Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998, 158: 1445-1448. 10.1001\/archinte.158.13.1445.","journal-title":"Arch Intern Med"},{"key":"21_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1365-2265.2002.01553.x","volume":"56","author":"V Wong","year":"2002","unstructured":"Wong V, Fu Xi-Li A, George J, Cheung NW: Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol. 2002, 56: 793-798. 10.1046\/j.1365-2265.2002.01553.x.","journal-title":"Clin Endocrinol"},{"key":"21_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000085538","volume":"63","author":"R Minelli","year":"2005","unstructured":"Minelli R, Valli MA, Di Secli C, Finardi L, Chiodera P, Bertoni R, Ferrari C, Barilli AL, Coiro V, Saccanti Jotti G, Delsignore R: Is steroid therapy needed in the treatment of destructive thyrotoxicosis induced by alpha-interferon in chronic hepatitis C?. Horm Res. 2005, 63: 194-199. 10.1159\/000085538.","journal-title":"Horm Res"},{"key":"21_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.amjmed.2004.01.023","volume":"117","author":"A Antonelli","year":"2004","unstructured":"Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E: Thyroid disorders in chronic hepatitis C. Am J Med. 2004, 117: 10-13. 10.1016\/j.amjmed.2004.01.023.","journal-title":"Am J Med"},{"key":"21_CR14","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/jc.80.3.922","volume":"80","author":"A Imagawa","year":"1995","unstructured":"Imagawa A, Itoh N, Hanafusa , Oda Y, Waguri M, Miyagawa J-I, Kono N, Kuwajima M, Matsuzawa Y: Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab. 1995, 80: 922-926. 10.1210\/jc.80.3.922.","journal-title":"J Clin Endocrinol Metab"},{"key":"21_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/eje.0.1320587","volume":"132","author":"D Preziati","year":"1995","unstructured":"Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Ninno ED, Meroni PL, Colombo M, Beck-Peccoz P: Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995, 132: 587-593.","journal-title":"Eur J Endocrinol"},{"key":"21_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1365-2265.1993.tb02423.x","volume":"39","author":"E Baudin","year":"1993","unstructured":"Baudin E, Marcellin P, Pouteau M, Colas-Linhardt N, Le Floch JP, Lemonnier C, Benhamou JP, Bok B: Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol. 1993, 39: 657-661.","journal-title":"Clin Endocrinol"},{"key":"21_CR17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5694\/j.1326-5377.2004.tb05866.x","volume":"108","author":"JD Topliss","year":"2004","unstructured":"Topliss JD, Eastman CJ: Diagnosis and management of hyperthyroidism and hypothyroidism. Med J Aust. 2004, 108: 186-193.","journal-title":"Med J Aust"},{"key":"21_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0889-8529(05)70240-1","volume":"26","author":"C Wang","year":"1997","unstructured":"Wang C, Crapo LM: The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am. 1997, 26: 189-218. 10.1016\/S0889-8529(05)70240-1.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"21_CR19","first-page":"107","volume":"2","author":"H Salabe-Lotz","year":"1999","unstructured":"Salabe-Lotz H, Salabe GB: Population of thyroid autoimmunity in Italy. Three year follow up. Thyroidology. 1999, 2: 107-112.","journal-title":"Thyroidology"},{"key":"21_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1530\/eje.0.1460743","volume":"146","author":"C Carella","year":"2002","unstructured":"Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G: The addition of ribavirin to interferon-\u03b1 therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol. 2002, 146: 743-749. 10.1530\/eje.0.1460743.","journal-title":"Eur J Endocrinol"},{"key":"21_CR21","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jc.2004-0627","volume":"89","author":"C Carella","year":"2004","unstructured":"Carella C, Mazziotti G, Amato G, Braverman EL, Roti E: Interferon-\u03b1-related thyroid disease: Pathophysiological, Epidemiological and Clinical Aspects. J Clin Endoc Metab. 2004, 89: 3656-3661. 10.1210\/jc.2004-0627.","journal-title":"J Clin Endoc Metab"},{"key":"21_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1086\/315516","volume":"181","author":"W Chehadeh","year":"2000","unstructured":"Chehadeh W, Weill J, Vantyghem M-C, Alm G, Lefebvre J, Wattre P, Hober D: Increased level of interferon-\u03b1 in blood of patients with insulin-dependent diabetes mellitus: Relationship with Coxsackievirus B infection. J Infect Dis. 2000, 181: 1929-1939. 10.1086\/315516.","journal-title":"J Infect Dis"},{"key":"21_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/105072503322238809","volume":"13","author":"FM Prummel","year":"2003","unstructured":"Prummel FM, Laurberg P: Interferon-alpha and Autoimmune Thyroid Disease. Thyroid. 2003, 13: 547-551. 10.1089\/105072503322238809.","journal-title":"Thyroid"},{"key":"21_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1365-2796.2002.00974.x","volume":"251","author":"O Dalgard","year":"2002","unstructured":"Dalgard O, Bjoro K, Hellum K, Myrvang B, Bjoro T, Haug E, Bell H: Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002, 251: 400-406. 10.1046\/j.1365-2796.2002.00974.x.","journal-title":"J Intern Med"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-5-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6823-5-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-5-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6823-5-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:24:57Z","timestamp":1630445097000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/1472-6823-5-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1186\/1472-6823-5-8","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,12]]},"assertion":[{"value":"13 May 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"8"}}